BR112015014232A2 - lesão renal aguda - Google Patents

lesão renal aguda

Info

Publication number
BR112015014232A2
BR112015014232A2 BR112015014232A BR112015014232A BR112015014232A2 BR 112015014232 A2 BR112015014232 A2 BR 112015014232A2 BR 112015014232 A BR112015014232 A BR 112015014232A BR 112015014232 A BR112015014232 A BR 112015014232A BR 112015014232 A2 BR112015014232 A2 BR 112015014232A2
Authority
BR
Brazil
Prior art keywords
kidney injury
acute kidney
lra
relates
present
Prior art date
Application number
BR112015014232A
Other languages
English (en)
Inventor
Dieterle Frank
Hoefling Holger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015014232A2 publication Critical patent/BR112015014232A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Veterinary Medicine (AREA)
  • Artificial Intelligence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

resumo patente de invenção: "lesão renal aguda". a presente invenção refere-se a métodos da avaliação da gravidade de lesão renal aguda (lra) em um indivíduo após cirurgia cardíaca. a presente invenção também se refere a um kit diagnóstico para medição quantitativa de biomarcadores, bem como a um dispositivo de teste rápido (point-of-care) para diagnóstico ou previsão de desenvolvimento de lesão renal aguda (lra) em um indivíduo após cirurgia cardíaca.
BR112015014232A 2012-12-20 2013-12-18 lesão renal aguda BR112015014232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740303P 2012-12-20 2012-12-20
PCT/EP2013/077253 WO2014096110A1 (en) 2012-12-20 2013-12-18 Acute kidney injury

Publications (1)

Publication Number Publication Date
BR112015014232A2 true BR112015014232A2 (pt) 2017-07-11

Family

ID=49885245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014232A BR112015014232A2 (pt) 2012-12-20 2013-12-18 lesão renal aguda

Country Status (20)

Country Link
US (1) US20150309052A1 (pt)
EP (1) EP2936160A1 (pt)
JP (2) JP6416778B2 (pt)
KR (1) KR20150096728A (pt)
CN (1) CN104871004A (pt)
AR (1) AR094118A1 (pt)
AU (2) AU2013360685A1 (pt)
BR (1) BR112015014232A2 (pt)
CA (1) CA2895096A1 (pt)
CL (1) CL2015001768A1 (pt)
HK (1) HK1209838A1 (pt)
IL (1) IL239431A0 (pt)
MA (1) MA38171B1 (pt)
MX (1) MX2015008108A (pt)
PH (1) PH12015501399A1 (pt)
RU (1) RU2015129496A (pt)
SG (1) SG11201504329RA (pt)
TN (1) TN2015000263A1 (pt)
TW (1) TW201430347A (pt)
WO (1) WO2014096110A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019037043A1 (zh) * 2017-08-24 2019-02-28 菲鹏生物股份有限公司 急性肾损伤的检测试剂盒
CN108986915B (zh) * 2018-07-24 2021-07-06 戴松世 人工智能的急性肾损伤的早期预测方法和装置
WO2020064995A1 (en) * 2018-09-28 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes
KR20200042725A (ko) 2018-10-16 2020-04-24 (주) 솔 렌즈 프리 cmos 광자 어레이 센서의 노이즈 특성 평가 방법
US20220301711A1 (en) * 2019-06-11 2022-09-22 The Regents Of The University Of California Systems and Methods for Machine Learning-based Identification of Acute Kidney Injury in Trauma Surgery and Burned Patients
CN110441457A (zh) * 2019-08-02 2019-11-12 深圳市绿航星际太空科技研究院 一种检测尿液中同型半胱氨酸的方法
CN112114125A (zh) * 2020-08-27 2020-12-22 中国医学科学院北京协和医院 一种评估肾脏储备功能的方法和系统及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033418A1 (en) * 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting a biological cell in a body fluid sample
AU2001295442A1 (en) * 2000-10-17 2002-04-29 Besst-Test Aps Assay for directly detecting an inflammatory indicator in a body fluid sample
EP1340086B1 (en) * 2000-10-17 2008-07-30 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US20090238812A1 (en) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
AU2009313189B2 (en) * 2008-11-10 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20110287964A1 (en) * 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
CN102292637B (zh) * 2008-11-21 2015-08-05 法蒂亚公司 用于检测或监测急性肾损伤的方法、装置和试剂盒
CN101706497A (zh) * 2009-11-05 2010-05-12 武汉三鹰生物技术有限公司 人tff3的elisa检测试剂盒
JP2013510322A (ja) * 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011143232A1 (en) * 2010-05-10 2011-11-17 Westerman Mark E Markers for acute kidney injury
EP2661620A4 (en) * 2011-01-08 2014-07-16 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL INSUFFICIENCY

Also Published As

Publication number Publication date
TW201430347A (zh) 2014-08-01
JP6416778B2 (ja) 2018-10-31
CL2015001768A1 (es) 2015-10-09
AU2013360685A1 (en) 2015-07-02
TN2015000263A1 (fr) 2016-10-03
US20150309052A1 (en) 2015-10-29
MA38171A1 (fr) 2016-11-30
CA2895096A1 (en) 2014-06-26
AU2017232081A1 (en) 2017-10-12
CN104871004A (zh) 2015-08-26
IL239431A0 (en) 2015-07-30
MX2015008108A (es) 2015-11-06
RU2015129496A (ru) 2017-01-26
KR20150096728A (ko) 2015-08-25
JP2019053067A (ja) 2019-04-04
JP2016503162A (ja) 2016-02-01
EP2936160A1 (en) 2015-10-28
PH12015501399A1 (en) 2015-09-07
SG11201504329RA (en) 2015-07-30
AR094118A1 (es) 2015-07-08
HK1209838A1 (en) 2016-04-08
MA38171B1 (fr) 2017-07-31
WO2014096110A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
BR112015014232A2 (pt) lesão renal aguda
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
BR112015028253A2 (pt) biomarcadores relacionados à função renal e métodos para utilização dos mesmos
EA201270020A1 (ru) Определение риска развития атеросклеротической болезни сердца
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
BR112014009643A2 (pt) métodos para diagnosticar ou detectar neoplasia colorretal em um sujeito humano, biomarcador para progressão de doença e kits para um diagnóstico de neoplasia colorretal
WO2012018535A3 (en) Wellness panel
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
WO2015034886A3 (en) Wellness panel for companion animals
WO2014158287A3 (en) A method for improving disease diagnosis using measured analytes
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
WO2013066879A3 (en) SOLUBLE UROKINASE RECEPTOR (suPAR) IN DIABETIC KIDNEY DISEASE
GB201201766D0 (en) Method
BR112015027249A2 (pt) método de diagnóstico de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.